Ab­b­Vie's Covid-19 an­ti­body part­ner wraps $221M Hong Kong IPO

Just a few days af­ter Ab­b­Vie went all in on a Covid-19 an­ti­body, its part­ner has of­fi­cial­ly wrapped its IPO.

List­ing on the Hong Kong Stock Ex­change, Har­bour Bio­Med has raised $221 mil­lion with help from nine cor­ner­stone in­vestors: Black­Rock Fund, HBM Health­care, Hill­house Cap­i­tal, Hud­son Bay Cap­i­tal, Oc­ta­gon In­vest­ments, An­lan Fund, Leg­end Cap­i­tal, Or­biMed and 3W Cap­i­tal.

The new in­jec­tion adds to over $300 mil­lion the com­pa­ny — which has of­fices in both Suzhou, Chi­na and Cam­bridge, MA — has ac­crued in four years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER